Mainstream Capital Management LLC Invests $1.04 Million in Pfizer Inc. (NYSE:PFE)

Mainstream Capital Management LLC bought a new position in Pfizer Inc. (NYSE:PFE - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 36,015 shares of the biopharmaceutical company's stock, valued at approximately $1,042,000.

Other institutional investors have also recently made changes to their positions in the company. Olistico Wealth LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer during the 2nd quarter valued at about $29,000. Quarry LP bought a new stake in shares of Pfizer during the 2nd quarter valued at about $31,000. Financial Connections Group Inc. bought a new stake in shares of Pfizer during the 2nd quarter valued at about $34,000. Finally, ESL Trust Services LLC bought a new stake in shares of Pfizer during the 1st quarter valued at about $37,000. Institutional investors own 68.36% of the company's stock.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Citigroup initiated coverage on Pfizer in a research note on Friday, October 25th. They set a "neutral" rating and a $30.00 price target on the stock. StockNews.com raised Pfizer from a "hold" rating to a "buy" rating in a research note on Wednesday, October 9th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 price target on shares of Pfizer in a research note on Wednesday, October 23rd. Daiwa Capital Markets raised Pfizer from a "neutral" rating to an "outperform" rating and increased their price objective for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Daiwa America raised Pfizer from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, August 7th. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, Pfizer has an average rating of "Moderate Buy" and an average price target of $33.58.

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.73 during trading hours on Friday, reaching $26.73. The company had a trading volume of 55,867,826 shares, compared to its average volume of 37,583,031. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The business has a fifty day simple moving average of $28.89 and a 200 day simple moving average of $28.63. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.60. The firm has a market cap of $151.48 billion, a PE ratio of 36.12, a price-to-earnings-growth ratio of 0.87 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business's revenue for the quarter was up 31.2% on a year-over-year basis. During the same period last year, the company earned ($0.17) earnings per share. On average, analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 6.29%. The ex-dividend date is Friday, November 8th. Pfizer's dividend payout ratio is 227.03%.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction on Wednesday, October 30th. The shares were acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company's stock, valued at approximately $282,400. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.06% of the stock is owned by corporate insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.